Table 4 Spearman rank correlation of surgery ESR1 expression/pre-selected gene signature scores and percentage of 2-week change in Ki67/residual Ki67 level in HER2− tumours
Surgery gene signature scores | HER2− (n = 135) | ||||||
|---|---|---|---|---|---|---|---|
Change in Ki67 (n = 121) | Residual Ki67 (n = 124) | ||||||
Signature name | Reference | Rho | p value | FDR | Rho | p value | FDR |
ESR1 | − 0.19 | 3.42E−02 | 4.62E−02 | − 0.17 | 6.53E−02 | 6.53E−02 | |
TP53-GS | Coutant et al. | − 0.47 | 7.43E−08 | 6.50E−07 | − 0.54 | 6.61E−11 | 3.57E−10 |
ERTarget27-GS | VerhaeghCR2014TableS2 | − 0.26 | 3.96E−03 | 8.22E−03 | − 0.25 | 5.25E−03 | 7.46E−03 |
SET-GS | Symmans et al. | − 0.25 | 5.38E−03 | 1.04E−02 | − 0.3 | 7.82E−04 | 1.41E−03 |
ESR1.2-GS | Desmedt et al. | − 0.24 | 8.58E−03 | 1.32E−02 | − 0.27 | 2.52E−03 | 4.00E−03 |
ESR1.1-GS | Mackay et al. | − 0.23 | 1.15E−02 | 1.63E−02 | − 0.29 | 1.34E−03 | 2.26E−03 |
ERGs-GS | Dunbier et al. | − 0.09 | 3.56E−01 | 3.70E−01 | − 0.21 | 1.96E−02 | 2.21E−02 |
PIK3CA-GS | Loi et al. | − 0.05 | 5.53E−01 | 5.53E−01 | − 0.18 | 4.07E−02 | 4.23E−02 |
MacTh1-GS | Iglesia et al. | 0.088 | 3.39E−01 | 3.66E−01 | 0.199 | 2.64E−02 | 2.85E−02 |
Inflammatory-GS | Dunbier et al. | 0.116 | 2.05E−01 | 2.31E−01 | 0.22 | 1.43E−02 | 1.68E−02 |
GDNF-GS | Morandi et al. | 0.116 | 2.04E−01 | 2.31E−01 | 0.254 | 4.40E−03 | 6.60E−03 |
obesity-GS | Creighton et al. | 0.134 | 1.43E−01 | 1.76E−01 | 0.239 | 7.61E−03 | 9.34E−03 |
Immune.2.STAT1-GS | Desmedt et al. | 0.158 | 8.26E−02 | 1.06E−01 | 0.247 | 5.64E−03 | 7.61E−03 |
E2F3-GS | Bild et al. | 0.237 | 8.79E−03 | 1.32E−02 | 0.24 | 7.38E−03 | 9.34E−03 |
IGF1-GS | Creighton et al. | 0.24 | 8.06E−03 | 1.32E−02 | 0.303 | 6.22E−04 | 1.20E−03 |
AKT/mTOR-GS | Majumder et al. | 0.249 | 5.83E−03 | 1.05E−02 | 0.362 | 3.63E−05 | 7.54E−05 |
PTEN-GS | Saale at al. | 0.286 | 1.49E−03 | 3.35E−03 | 0.392 | 6.68E−06 | 1.50E−05 |
PI3K-GS | Creighton 2010 | 0.291 | 1.21E−03 | 2.97E−03 | 0.413 | 1.92E−06 | 4.71E−06 |
AURKA-GS | Desmedt et al. | 0.32 | 3.53E−04 | 9.53E−04 | 0.427 | 7.36E−07 | 1.99E−06 |
E2Factivation-GS | Miller et al. | 0.323 | 3.08E−04 | 9.24E−04 | 0.432 | 5.39E−07 | 1.62E−06 |
E2FmotifCellCycleAssociated-GS | Miller et al. | 0.402 | 4.79E−06 | 1.62E−05 | 0.454 | 1.22E−07 | 4.12E−07 |
Gene70-GS | van ‘t Veer et al. | 0.431 | 8.22E−07 | 3.17E−06 | 0.546 | 5.64E−11 | 3.57E−10 |
CIN70-GS | Carter et al. | 0.442 | 3.89E−07 | 1.75E−06 | 0.529 | 2.79E−10 | 1.08E−09 |
E2F4activation-GS | Guerrero-Zotano et al. | 0.454 | 1.73E−07 | 9.34E−07 | 0.535 | 1.51E−10 | 6.80E−10 |
GGI-GS | Sotiriou et al. | 0.462 | 9.63E−08 | 6.50E−07 | 0.571 | 4.52E−12 | 6.10E−11 |
JClinInvest2007RBloss-GS | Bosco et al. | 0.491 | 1.12E−08 | 1.51E−07 | 0.545 | 5.89E−11 | 3.57E−10 |
DiLeoRBloss-GS | Malorni et al. | 0.526 | 5.61E−10 | 1.51E−08 | 0.584 | 1.08E−12 | 2.92E−11 |